NeurologyLive® Friday 5 — December 20, 2024

NeurologyLive® Friday 5 — December 20, 2024


Welcome to NeurologyLive®‘s Friday 5! Each week, the workers compiles 5 highlights of NeurologyLive®‘s widespread protection in neurology, starting from newsworthy examine findings and FDA motion to professional interviews and peer-to-peer panel discussions.

1: Utilizing the PERC Database to Collect Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of consultants talked about 2 research offered at AES 2024 that used the Pediatric Epilepsy Analysis Consortium genetics database to check elements influencing latency in genetic testing and drug-resistant epilepsy. [WATCH TIME: 5 minutes]

NeurologyLive® Friday 5 — December 20, 2024

2: Addressing Disparities and Bettering Care By way of Pediatric Epilepsy Analysis: Adam Numis, MD; Laura Kirkpatrick, MD

At AES 2024, a duo of pediatric epilepsy specialists highlighted a Pediatric Epilepsy Analysis Consortium overview on the necessity for standardized socio-demographic knowledge and higher follow-up for at-risk infants. [WATCH TIME: 5 minutes]

NeurologyLive® Friday 5 — December 20, 2024

3: Insights From Little one Neurology Basis on Advancing Holistic Epilepsy Care: Jessica Nickrand, PhD; Allyson Eyermann

A duo from the Little one Neurology Basis mentioned multidisciplinary collaboration, improvements in epilepsy care, and the significance of holistic, family-centric approaches to enhancing affected person outcomes at AES 2024. [WATCH TIME: 5 minutes]

NeurologyLive® Friday 5 — December 20, 2024

4: NeuroVoices: Barry Ticho, MD, PhD, on the Illness-Modifying Potential of STK-001 in Treating Dravet Syndrome

In our newest Q&A for NeuroVoices, the chief medical officer at Stoke Therapeutics sat down at AES 2024 to debate the promising knowledge behind STK-001, an investigational antisense oligonucleotide in growth for Dravet syndrome.

NeurologyLive® Friday 5 — December 20, 2024

5: Advancing Epilepsy Therapy With Novel Approaches and Predictive Applied sciences: Jacqueline A. French, MD

The professor of neurology at NYU Grossman Faculty of Medication mentioned how revolutionary startups are utilizing proof-of-concept research and gadgets like responsive neurostimulators to enhance affected person outcomes. [WATCH TIME: 6 minutes]

NeurologyLive® Friday 5 — December 20, 2024



Supply hyperlink

Deixe um comentário

O seu endereço de e-mail não será publicado. Campos obrigatórios são marcados com *